| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
UPB
Upstream Bio, Inc.
|
Aug 14, 2026 | HOLD |
Strong Buy
+373.8% avg upside
9 analysts
|
$9.00
31.22% Upside
|
+0.0% | · |
|
OCS
Oculis Holding
|
Aug 14, 2026 | BUY |
Strong Buy
+192.5% avg upside
11 analysts
|
$20.00
57.39% Upside
|
+0.0% | · |
|
SRRK
Scholar Rock Holding
|
Aug 13, 2026 | BUY |
Strong Buy
+8.4% avg upside
23 analysts
|
$63.00
21.78% Upside
|
-1.0% | · |
|
CYTK
Cytokinetics
|
Aug 13, 2026 | BUY |
Strong Buy
+23.3% avg upside
36 analysts
|
$103.00
41.13% Upside
|
+0.9% | · |
|
XENE
Xenon
|
Aug 11, 2026 | BUY |
Strong Buy
-3.0% avg upside
28 analysts
|
$82.00
30.21% Upside
|
-1.4% | · |
|
DYN
Dyne Therapeutics
|
Jul 30, 2026 | HOLD |
Strong Buy
+53.5% avg upside
31 analysts
|
— | -0.1% | · |
|
EYPT
EyePoint Pharmaceuticals
|
Jul 22, 2026 | BUY |
Strong Buy
+151.2% avg upside
20 analysts
|
$30.00
123.13% Upside
|
+16.5% | · |
|
BHVN
Biohaven Ltd.
|
Jun 30, 2026 | BUY |
Strong Buy
+55.3% avg upside
25 analysts
|
— | -1.6% | · |
|
LRMR
Larimar Therapeutics
|
Jun 29, 2026 | BUY |
Strong Buy
+318.0% avg upside
22 analysts
|
$9.00
114.33% Upside
|
+36.2% | · |
|
LXEO
Lexeo Therapeutics, Inc.
|
Jun 25, 2026 | BUY |
Strong Buy
+292.1% avg upside
11 analysts
|
$9.00
85.92% Upside
|
+3.0% | · |
|
AGIO
Agios Pharma
|
Jun 11, 2026 | HOLD |
Strong Buy
+85.1% avg upside
29 analysts
|
$31.00
6.28% Downside
|
+16.9% | · |
|
NRIX
Nurix Therapeutics
|
Jun 11, 2026 | BUY |
Strong Buy
+19.2% avg upside
28 analysts
|
— | +59.3% | · |
|
SPTX
Seaport Therapeutics, Inc.
|
Jun 08, 2026 | BUY |
Strong Buy
+61.9% avg upside
6 analysts
|
$42.00
76.68% Upside
|
+45.8% | · |
|
EWTX
Edgewise Therapeutics
|
Jun 05, 2026 | BUY |
Strong Buy
+4.9% avg upside
15 analysts
|
$53.00
25.73% Upside
|
+24.1% | · |
|
NMRA
Neumora Therapeutics, Inc.
|
May 26, 2026 | SELL |
Buy
+342.5% avg upside
11 analysts
|
— | +13.0% | · |
|
RCKT
Rocket Pharmaceuticals
|
Apr 02, 2026 | SELL |
Buy
+397.3% avg upside
29 analysts
|
— | +2.2% | · |
|
SEPN
Septerna, Inc.
|
Mar 24, 2026 | BUY |
Strong Buy
+9.1% avg upside
12 analysts
|
$38.00
16.08% Downside
|
+89.8% | · |
|
ACAD
ACADIA Pharmaceuticals
|
Mar 04, 2026 | BUY |
Strong Buy
+28.3% avg upside
43 analysts
|
$34.00
21.75% Upside
|
+20.7% | · |
|
PRME
Prime Medicine, Inc.
|
Nov 18, 2025 | HOLD |
Strong Buy
+208.9% avg upside
16 analysts
|
— | -13.0% | · |
|
MCRB
Seres Therapeutics
|
Oct 23, 2024 | SELL |
Buy
+269.7% avg upside
11 analysts
|
— | -17.1% | · |
|
SANA
Sana Biotechnology
|
Oct 18, 2024 | HOLD |
Strong Buy
+169.8% avg upside
14 analysts
|
— | +18.9% | · |
|
ATRA
Atara Biotherapeutics
|
Jul 13, 2022 | HOLD |
Buy
+110.7% avg upside
18 analysts
|
$10.00
17.55% Upside
|
-48.8% | · |
|
RIGL
Rigel
|
Nov 09, 2020 | HOLD |
Strong Buy
-40.3% avg upside
17 analysts
|
— | +24.9% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.